Utama › Kanser Ginjal (Karsinoma Sel Renal) › South Carolina
Kajian klinikal Kanser Ginjal (Karsinoma Sel Renal) di South Carolina
12 kajian untuk Kanser Ginjal (Karsinoma Sel Renal) sedang mencari peserta di lokasi di South Carolina.
Bandar di South Carolina
Teks kajian rasmi (Bahasa Inggeris)
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 South Carolina Site, Myrtle Beach
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07300241A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Prisma Health Cancer Institute, Greenville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07419841Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AnMed Health Cancer Center, Anderson
- Prisma Health Richland Hospital, Columbia
- McLeod Regional Medical Center, Florence
- dan 12 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #9, Myrtle Beach
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Medical University of South Carolina, Charleston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT03866382A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- MUSC Hollings Cancer Center, Charleston
- Carolina Urologic Research Center, LLC, Myrtle Beach
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07293351Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Medical University of South Carolina, Charleston
- Self Regional Healthcare, Greenwood
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Grand Strand Medical Center, Myrtle Beach
- Carolina Urologic Research Center, LLC, Myrtle Beach
- Parkway Surgery Center, Myrtle Beach
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07227415ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Carolina Urologic Research Center, Myrtle Beach
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- MUSC Hollings Cancer Center, Charleston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06750185Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- dan 10 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06661720Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Medical University of South Carolina, Charleston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT04510597Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.